Vivos Therapeutics, Inc. (VVOS) Stock Analysis

Company Overview

The market values Vivos Therapeutics, Inc. (VVOS) at $4.53M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 268.

The 52-week range on file runs from $0.12 to $3.11. The most recent close on file for VVOS is $0.13, dated October 21, 2026. That is −$0.01 (−4.20%) against the previous close. The latest close sits 8.63% above that 52-week low.

Financial Health

In fiscal 2025, Vivos Therapeutics, Inc. reported revenue of $17.44M. Against the prior fiscal year total of $15.03M, that is a change of +16.05%. The same year closed with a net loss of $21.23M. Profit margin runs at −121.79%. That is 107 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −1.95.

Across the 4 fiscal years on file, revenue moves from $16.02M in 2022 to $17.44M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.22 times revenue. On price-to-sales that is 0.1 times the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −95.12%. Measured over 5 years, that is −73.15% a year compounded. Daily returns over the trailing 5 years annualize to a volatility of 399.73%.

Growth & Income

The record shows no dividend for VVOS.

Across the complete calendar years on file, 2023 returned +23.78% and 2022 returned −82.13%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −93.36%.